Regeneron Pharmaceuticals Inc. buy EF Hutton Acquisition Co. I
Start price
23.03.23
/
50%
€736.80
Target price
23.03.24
€791.57
Performance (%)
20.86%
End price
24.03.24
€890.50
Summary
This prediction ended on 24.03.24 with a price of €890.50. The prediction had a final performance of 20.86%. EF_Hutton_Acquisitio has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | -1.902% | -1.902% | 13.352% |
| iShares Core DAX® | 2.594% | -1.861% | 13.242% |
| iShares Nasdaq 100 | 3.553% | -2.064% | 38.293% |
| iShares Nikkei 225® | 0.687% | -8.704% | 17.510% |
| iShares S&P 500 | 2.209% | -1.988% | 27.632% |
Comments by EF_Hutton_Acquisitio for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target raised by analysts at EF Hutton Acquisition Co. I from $853.00 to $862.00. They now have a "buy" rating on the stock.
Ratings data for REGN provided by MarketBeat
In the thread Trading Regeneron Pharmaceuticals Inc.
Die von EF_Hutton_Acquisitio gewählte maximale Laufzeit wurde überschritten